Kangmei's real accuser, Ma Xingtian, was sentenced to up to three years in a sentence of mandatory measures.

The announcement revealed that Mr. Ma has not held any position sat in the company since May 2020.
the current normal production and operation of the company, the company's directors, supervisors, senior managers will strengthen the company's management, to ensure the continued and stable development of all business.
public information shows that Ma Xingtian was born in 1969, Guangdong Puning people.
graduated from Macau University of Science and Technology with a major in business administration, and was the chairman and general manager of Kangmei Pharmaceutical Co., Ltd. and the founder of Kangmei PharmaceuticalCo. on May 15,
, ST Kangmei announced that the company's directors Ma Xingtian, Xu Dongxuan and other senior executives submitted their resignation reports.
for personal reasons, Ma Xingtian resigned as chairman, general manager, nomination committee and member of the Strategy Committee, and Xu Dongxuan resigned as vice chairman, executive vice-president and member of the remuneration and appraisal committee.
Kangmei Pharmaceuticals related to the big event combing: March 19, 2001, Kangmei Pharmaceuticals shares listed on the Shanghai Stock Exchange, the main business for Chinese medicine tablets, Traditional Chinese medicine, chemicals and other products production and sales, the company's actual control of the people for Ma Xingtian, Xu Dongjin couple.
in August last year, the CSRC issued an administrative penalty notice to Kangmei Pharmaceuticals, according to the findings of the notice, from 2016 to the first half of 2018, Kangmei Pharmaceuticals increased its revenue by 8,999 million yuan, 10,032 million yuan, 8.484 billion yuan, respectively, the 2018 annual report increased revenue of 1.613 billion yuan;
may 14 this year, the CSRC in accordance with the law on Kangmei Pharmaceuticals illegal violations of the case to make administrative penalties and market ban decision, decided to Kangmei Pharmaceuticals ordered to correct, give a warning, and a fine of 600,000 yuan, 21 responsible personnel were fined 900,000 yuan to 100,000 yuan, the six main responsible persons to take 10 to life securities market ban measures.
related intermediary agencies suspected of illegal violations are in the administrative investigation and trial proceedings.
at the same time, the CSRC has transferred Kangmei Pharmaceuticals and related personnel to the judicial authorities for suspected criminal acts.
According to the Administrative Penalty Decision of May 14, the charges concerning the perpetrator are "the crime of illegal disclosure and non-disclosure of important information" and the criminal law "The crime of illegal disclosure and non-disclosure of important information" shall be: "Companies and enterprises with information disclosure obligations in accordance with the law shall provide false or concealment of important matters to shareholders and the public." If the financial and accounting reports of the facts, or other important information that should be disclosed in accordance with the law, are not disclosed in accordance with the provisions, seriously harm the interests of shareholders or other persons, or if there are other serious circumstances, the persons in charge directly responsible for them and other persons directly responsible shall be sentenced to fixed-term imprisonment of not more than three years or criminal detention, and shall be sentenced to a fine of not less than 20,000 yuan and not more than 200,000 yuan.
According to the Administrative Penalty Decision, Kangmei Pharmaceuticals, in addition to involving financial fraud and false disclosure, also involved controlling shareholders and their related parties to occupy 11.619 billion yuan of listed companies.
before being investigated, The market value of Kangmei up to more than 130 billion yuan, is recognized in the industry as a hundred billion market value white horse shares.
it is worth noting that there are false records in Kangmei Pharmaceuticals' 2018 report, which inflated fixed assets, construction projects under construction, and investment real estate, totalling 3.6 billion yuan.
also through financial non-accounting, false accounting, forgery, alteration of large fixed deposit slips or bank statements, with operating income fraud and counterfeit sales returns, etc., the false increase in monetary funds amounted to 22.549 billion yuan, 29.944 billion yuan, 36.188 billion yuan, a total of 88.681 billion yuan.
Note: Sina medicine comprehensive finishing.